Active	Status	Sponsor type	Region	Phase	Filter
4 Active 0 Inactive 4 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ma, Xinmei
NCT05247216: A Phase 2 Study of Hemay007 in Patients With Rheumatoid Arthritis	Completed	2	140	RoW	Hemay007 800 mg QD group, Hemay007 1200 mg QD group, Hemay007 600 mg QD group, Hemay007 placebo group	Tianjin Hemay Pharmaceutical Co., Ltd	Rheumatoid Arthritis	06/23	06/23
NCT05849727: A Clinical Study of TQH3821 Tablets in the Treatment of Treated Rheumatoid Arthritis	Recruiting	2	180	RoW	TQH3821 tablets 200 mg, TQH3821 tablets matching placebo	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.	Rheumatoid Arthritis	06/24	12/24
LUMRY, W
PREPARED-1, NCT06339008: A Study of Lebrikizumab in Adult Participants With Perennial Allergic Rhinitis	Recruiting	3	450	Europe, US, RoW	LY3650150, Placebo, Standard therapy for INCS	Eli Lilly and Company	Perennial Allergic Rhinitis (PAR)	05/25	05/26